1228561-05-4 Usage
Description
(R)-1-AMINO-INDAN-4-OL, also known as (R)-4-Aminotetralin, is a chiral chemical compound belonging to the class of amino alcohols. It possesses a specific stereochemistry, featuring a non-superimposable mirror image, which makes it a valuable molecule in the fields of medicinal and synthetic chemistry. (R)-1-AMINO-INDAN-4-OL is utilized in the synthesis of pharmaceuticals and serves as a fundamental building block in organic chemistry. Its potential applications extend to the development of drugs for various medical conditions, and it is also employed in research and development efforts aimed at discovering new compounds with therapeutic properties.
Uses
Used in Pharmaceutical Synthesis:
(R)-1-AMINO-INDAN-4-OL is used as a key intermediate for the development of pharmaceuticals targeting a range of medical conditions. Its unique structural and stereochemical features enable the creation of novel drug candidates with improved efficacy and selectivity.
Used in Organic Chemistry:
As a building block in organic chemistry, (R)-1-AMINO-INDAN-4-OL is used for the synthesis of various complex organic molecules. Its chiral nature allows for the development of enantiomerically pure compounds, which are essential in many biological and pharmaceutical applications.
Used in Drug Development:
(R)-1-AMINO-INDAN-4-OL is employed as a starting material in the development of new drugs for the treatment of various medical conditions. Its potential applications in this field are vast, as it can be modified and functionalized to create a diverse array of therapeutically relevant compounds.
Used in Research and Development:
In the realm of research and development, (R)-1-AMINO-INDAN-4-OL serves as a valuable tool for exploring new compounds with therapeutic properties. Its unique structural features make it an ideal candidate for studying the structure-activity relationships of potential drug candidates and for identifying novel pharmacological targets.
Overall, (R)-1-AMINO-INDAN-4-OL is a versatile and important compound in the fields of medicinal chemistry, pharmaceutical synthesis, and drug development, with a wide range of applications and potential for further exploration.
Check Digit Verification of cas no
The CAS Registry Mumber 1228561-05-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,5,6 and 1 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1228561-05:
(9*1)+(8*2)+(7*2)+(6*8)+(5*5)+(4*6)+(3*1)+(2*0)+(1*5)=144
144 % 10 = 4
So 1228561-05-4 is a valid CAS Registry Number.
1228561-05-4Relevant articles and documents
5,7-DIHYDRO-6H-PYRROLO[2,3-D]PYRIMIDIN-6-ONE DERIVATIVES FOR MARK INHIBITION
-
Page/Page column 49, (2010/01/07)
Compounds of formula I: are potent and selective inhibitors of microtubule affinity regulating kinase (MARK), and hence find use in treatment of Alzheimer's disease and other conditions associated with hyperphosphorylation of tau.
Novel Cerebroprotective Agents with Central Nervous System Stimulating Activity. 1. Synthesis and Pharmacology of 1-Amino-7-hydroxyindan Derivatives
Oshiro, Yasuo,Sakurai, Youji,Tanaka, Tatsuyoshi,Ueda, Hiraki,Kikuchi, Tetsuro,Tottori, Katura
, p. 2004 - 2013 (2007/10/02)
To developed a novel cerebroprotective agent with central nervous system (CNS) stimulating activity, a series of 1-amino-7-hydroxyindan derivatives was synthesized, and their effects on the survival time of mice under hypoxic conditions were tested.CNS-stimulating activity was also evaluated by examining the promotional effect on the recovery from cerebral concussion induced coma in mice.Several compounds prolonged the survival time of mice in hypoxic conditions at a dose of 30 mg/kg (sc or ip) and 100 mg/kg (po).They also exhibited the promotional effects on recovery from coma at a dose of 100 mg/kg po.The three most potent compounds in both tests, 1-amino-7-hydroxy-6-(1-methylpropyl)indan (20), 1-amino-7-hydroxy-4,6-dimethyl-2-phenylindan (30), and 1-amino-7-hydroxy,2,2,4,6-tetramethylindan (35) were selected for further investigations.Structure-activity relationships were also discussed.
